Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltrombopag for CLL-associated Thrombocytopenia
NCT01168921Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2010
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eltrombopag in Thrombocytopenia, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Number of Participants With a Response. Started Nov 2010; status: completed.
02
Drugs
eltrombopag
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on NCT01168921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01168921.